Relay Therapeutics, Inc. Debt Securities, Available-for-sale, Unrealized Loss Position
Relay Therapeutics, Inc. (RLAY) had Debt Securities, Available-for-sale, Unrealized Loss Position of $686.51 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities › Debt Securities, Available-for-Sale, Unrealized Loss Position
us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition · last filed 2026-08-06
- 2026-06-30: Debt Securities, Available-for-sale, Unrealized Loss Position $686.51M.
- 2026-03-31: Debt Securities, Available-for-sale, Unrealized Loss Position $273.67M.
- 2025-12-31: Debt Securities, Available-for-sale, Unrealized Loss Position $43.26M.
- 2025-09-30: Debt Securities, Available-for-sale, Unrealized Loss Position $225.76M.
| Period end | Debt Securities, Available-for-sale, Unrealized Loss Position | Debt Securities, Available-for-sale, Unrealized Loss Position as first filed |
|---|---|---|
| 2026-06-30 | $686.51M 10-Q · filed 2026-08-06 | |
| 2026-03-31 | $273.67M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $43.26M 10-Q · filed 2026-08-06 | |
| 2025-09-30 | $225.76M 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $266.22M 10-Q · filed 2025-08-07 | |
| 2025-03-31 | $240.41M 10-Q · filed 2025-05-05 | |
| 2024-12-31 | $293.65M 10-K · filed 2026-02-26 | |
| 2024-09-30 | $226.96M 10-Q · filed 2024-11-06 | |
| 2024-06-30 | $500.24M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $483.94M 10-Q · filed 2024-05-02 | |
| 2023-12-31 | $373.55M 10-K · filed 2025-02-26 | |
| 2023-09-30 | $655.49M 10-Q · filed 2023-11-02 | |
| 2023-06-30 | $725.67M 10-Q · filed 2023-08-08 | |
| 2023-03-31 | $548.65M 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $706.31M 10-K · filed 2024-02-22 | |
| 2022-09-30 | $689.38M 10-Q · filed 2022-11-03 | |
| 2022-06-30 | $730.25M 10-Q · filed 2022-08-04 | |
| 2022-03-31 | $778.73M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $677.95M 10-K · filed 2023-02-23 | $667.00M 10-K · filed 2022-02-24 |
| 2020-12-31 | $70.50M 10-K · filed 2022-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |